Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) EBT Margin (2016 - 2020)

Historic EBT Margin for KalVista Pharmaceuticals (KALV) over the last 7 years, with Q2 2020 value amounting to 224.74%.

  • KalVista Pharmaceuticals' EBT Margin rose 1470700.0% to 224.74% in Q2 2020 from the same period last year, while for Apr 2020 it was 305.0%, marking a year-over-year decrease of 1287300.0%. This contributed to the annual value of 3112.39% for FY2025, which is 33656800.0% up from last year.
  • KalVista Pharmaceuticals' EBT Margin amounted to 224.74% in Q2 2020, which was up 1470700.0% from 783.26% recorded in Q1 2020.
  • KalVista Pharmaceuticals' EBT Margin's 5-year high stood at 60.0% during Q2 2018, with a 5-year trough of 94342.86% in Q1 2016.
  • Over the past 5 years, KalVista Pharmaceuticals' median EBT Margin value was 371.8% (recorded in 2019), while the average stood at 6669.14%.
  • In the last 5 years, KalVista Pharmaceuticals' EBT Margin plummeted by -202857100bps in 2016 and then skyrocketed by 54920000bps in 2018.
  • Quarter analysis of 5 years shows KalVista Pharmaceuticals' EBT Margin stood at 2038.07% in 2016, then soared by 74bps to 526.71% in 2017, then skyrocketed by 84bps to 83.85% in 2018, then tumbled by -167bps to 224.08% in 2019, then fell by 0bps to 224.74% in 2020.
  • Its EBT Margin was 224.74% in Q2 2020, compared to 783.26% in Q1 2020 and 224.08% in Q4 2019.